Form 4: Summit Therapeutics Co-CEO's Spouse Exercises Stock Options, Increasing Indirect Stake

Mahkam Zanganeh, Co-Chief Executive Officer of Summit Therapeutics Inc., reported that her spouse exercised options to acquire 74,545 shares of common stock, with the shares retained.

Summary

• Mahkam Zanganeh, Co-Chief Executive Officer, Director, and 10% Owner of Summit Therapeutics Inc. (SMMT), filed a Form 4.
• The filing reports a transaction on May 30, 2025, where the reporting person's spouse exercised an option to purchase 74,545 shares of Summit Therapeutics common stock.
• The exercise price for these shares was $2.64 per share.
• The underlying shares acquired through the option exercise were not sold by the spouse.
• Following this transaction, the reporting person's direct beneficial ownership stands at 31,000 shares of Common Stock.
• Indirect beneficial ownership includes 555,754,696 shares held by spouse, 10,199,776 shares by the Shaun Zanganeh Irrevocable Trust (with Reporting Person as Trustee), 25,457,666 shares by the Mahkam Zanganeh Revocable Trust (with Reporting Person as Trustee), and 50,000 shares by an immediate family member.
• The reporting person disclaims beneficial ownership of these indirectly held securities, except to the extent of her pecuniary interest therein.
• The option was granted on January 2, 2024, and vested in four equal quarterly installments on March 31, June 30, September 30, and December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is a routine disclosure, the fact that a key insider's spouse exercised options and *retained* the shares, rather than selling them, suggests confidence in the company's future value. This action aligns insider interests with long-term shareholder value.

Positives

• The exercise of stock options by a high-level insider's spouse, without an immediate sale of the underlying shares, can be interpreted as a sign of confidence in the company's future prospects and value.
• The retention of shares post-exercise indicates a long-term commitment to the company's equity by a key insider.

Negatives

• The document itself does not present any inherently negative information regarding the company's operations or financial health, as it is solely an insider transaction report.

Future Outlook

This Form 4 filing primarily reports a past transaction and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person's spouse exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share.
• The Reporting Person's spouse did not sell the underlying shares.
• The Reporting Person disclaims beneficial ownership of certain indirectly held securities, except to the extent of her pecuniary interest therein.

Industry Context

In the biotechnology and pharmaceutical industry, insider transactions like option exercises can signal management's confidence in upcoming clinical trial results, regulatory approvals, or commercialization efforts. The decision to hold shares post-exercise, rather than sell, is often viewed positively by investors as it aligns insider interests with shareholder value creation.

Related Party Transactions

• The transaction involves the spouse of the Co-Chief Executive Officer, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction may be viewed as a positive signal of insider confidence, potentially influencing investor sentiment.
• Management/Employees: The exercise and retention of shares by a key executive's spouse reinforces alignment with company performance.

Key Dates

Keywords

Summit Therapeutics, SMMT, SEC Form 4, Insider Transaction, Stock Option Exercise, Beneficial Ownership, Mahkam Zanganeh, Biotechnology, Pharmaceuticals